Page last updated: 2024-11-05

dihydrostreptomycin sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dihydrostreptomycin sulfate is a semisynthetic aminoglycoside antibiotic derived from streptomycin. It is produced by reducing the streptomycin molecule, which enhances its activity against certain bacteria. Dihydrostreptomycin is particularly effective against Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. Its mechanism of action involves binding to the 16S ribosomal RNA of bacteria, preventing the formation of the initiation complex needed for protein synthesis. Dihydrostreptomycin sulfate is used in the treatment of tuberculosis, especially multidrug-resistant strains. It is often administered in combination with other antibiotics to improve efficacy and reduce the risk of resistance development. However, dihydrostreptomycin sulfate can cause serious side effects, including ototoxicity (damage to the auditory nerve) and nephrotoxicity (damage to the kidneys). Therefore, its use is carefully monitored and often reserved for severe cases of tuberculosis.'

Dihydrostreptomycin Sulfate: A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21653
CHEMBL ID3188576
MeSH IDM0006415

Synonyms (48)

Synonym
D02512
dihydrostreptomycin sulfate (usp)
5490-27-7
dihydrostreptomycin sulfate
d-streptamine, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1-2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1-4)-n,n'-bis(aminoiminomethyl)-, sulfate (2:3) (salt)
dihydrostreptomycin sequisulphate
dihydrostreptomycin sulfate [usp]
einecs 226-823-7
didromycine
ai3-50133
dihydrostreptomycin sesquisulfate
panstreptin
dihydrostreptomycin 3/2 sulfate
didromycin
dihydrostreptomycin sulfate (2:3)(salt)
sulfate, dihydrostreptomycin
nsc-756739
dtxsid6045824 ,
dtxcid4025824
tox21_111309
d-streptamine, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1.fwdarw.4)-n,n'-bis(aminoiminomethyl)-, sulfate (2:3) (salt)
dihydrostreptomyzinsulfat
t7d4876iue ,
d-streptamine, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1->4)-n1,n3-bis(aminoiminomethyl)-, sulfate (2:3)
dihydrostreptomycinium sulfuricum
unii-t7d4876iue
dihydrostreptomycin sulphate (2:3)(salt)
dihydrostreptomycin sulfate [green book]
dihydrostreptomycin sulfate [usp monograph]
dihydrostreptomycin sulfate [mart.]
dihydrostreptomycin sesquisulfate [mi]
dihydrostreptomycin sulfate [usp-rs]
dihydrostreptomycin sulfate [who-dd]
d-streptamine, o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1.fwdarw.2)-o-5-deoxy-3-c-(hydroxymethyl)-.alpha.-l-lyxofuranosyl-(1.fwdarw.4)-n,n'-bis(aminoiminomethyl)-, sulfate (2:3) (salt)
dihydrostreptomycin sulfate, antibiotic for culture media use only
W-105598
CHEMBL3188576
mfcd00070252
AKOS026750384
1,1'-((1r,2r,3s,4r,5r,6s)-4-(((2r,3r,4r,5s)-3-(((2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydro-2h-pyran-2-yl)oxy)-4-hydroxy-4-(hydroxymethyl)-5-methyltetrahydrofuran-2-yl)oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine se
Q27289765
2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid
AKOS037515800
d-streptamine, o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1-2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1-4)-n,n'-bis(aminoiminomethyl)-, sulfate(2:3)(salt)
dihydrostreptomycin sulfate (usp monograph)
dihydrostreptomycin sulfate (mart.)
pfizer-strep
dihydrostreptomycin sulfate (usp-rs)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Severe pathologic conditions, over-dosage, or concomitant exposure to other potent drugs may predispose a patient to these acute adverse effects."( Acute adverse effects of antibiotics.
Adams, HR, 1975
)
0.25

Compound-Compound Interactions

ExcerptReferenceRelevance
" After development of acute mastitis, procaine PEN alone or combined with DHS were given IM, and the concentrations of PEN and DHS in plasma and normal and mastitic milk were determined."( Effect of procaine benzylpenicillin alone or in combination with dihydrostreptomycin on udder pathogens in vitro and in experimentally infected bovine udders.
Aström, G; Franklin, A; Olof, H; Rantzien, MH, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of penicillin and dihydrostreptomycin from three penicillin/ aminoglycoside fixed combination products for intramuscular injection was investigated in a four-way, randomized, crossover experiment in rabbits."( Bioavailability in the rabbit of penicillin and dihydrostreptomycin from three commercial penicillin/aminoglycoside fixed combination products for intramuscular injection.
De Neeling, AJ; Groen, K; Pereboom-De Fauw, DP; Van Veen-Rutgers, A; Vulto, AG, 1996
)
0.29
" Therefore, these products are not bioequivalent with respect to the rate of absorption of penicillin."( Bioequivalence study in calves of three commercial penicillin/dihydrostreptomycin fixed combination products for intramuscular injection.
DeNeeling, AJ; Groen, K; Mevius, DJ; Pereboom-De-Fauw, DP; Vulto, AG, 1996
)
0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Effects of dihydrostreptomycin, etacrine acid and ATPh on the endocochlear potential in guinea-pigs depended on the dosage and means of administration."( [Relationship between the endocochlear potential and metabolism in the vascular stria of the inner ear].
Mazo, IL; Sagalovich, BM, 1977
)
0.26
" The dosage schedule used involved two intraperitoneal administrations of SPLV-entrapped aminoglycosides at three-day intervals."( Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides.
Fountain, AG; Fountain, MW; Lenk, RP; Shen, A; Weiss, SJ, 1985
)
0.27
" The liposomal preparations thus formed may be useful as intravenous dosage forms of the antibiotics."( [Production of liposomal preparations of streptomycin and dihydrostreptomycin].
Griazmova, NS; Ladygina, GA; Petiushenko, RM; Tentsova, AI; Vladimirskiĭ, MA, 1984
)
0.27
" In addition, six different case scenarios were presented with questions to their potential antibiotic usage, active substance/preparation and the dosing scheme."( [Survey on the use of antibiotics among Swiss equine veterinarians].
Kunz, T; Schoster, A; Torgerson, PR, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.88320.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,201)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901083 (90.17)18.7374
1990's51 (4.25)18.2507
2000's33 (2.75)29.6817
2010's26 (2.16)24.3611
2020's8 (0.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.83 (24.57)
Research Supply Index7.21 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index81.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (1.13%)5.53%
Reviews22 (1.65%)6.00%
Case Studies11 (0.83%)4.05%
Observational0 (0.00%)0.25%
Other1,284 (96.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]